Back to top
more

Cencora, Inc. (COR)

(Real Time Quote from BATS)

$236.81 USD

236.81
55,642

-4.29 (-1.78%)

Updated Aug 8, 2024 09:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

All You Need to Know About Cencora (COR) Rating Upgrade to Buy

by Zacks Equity Research

Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Compared to Estimates, Cencora (COR) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 5.03% and 0.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?

by Indrajit Bandyopadhyay

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?

by Zacks Equity Research

Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.

Why Cencora (COR) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cencora (COR) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Cencora (COR) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Cencora (COR) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Embecta Corp. (EMBC): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Embecta Corp. (EMBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings

by Zacks Equity Research

Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.

Will High Medical Care Costs Hurt Molina's (MOH) Q2 Earnings?

by Zacks Equity Research

Molina's (MOH) second-quarter performance is likely to have been affected by high medical care costs, partly offset by rising membership in all three businesses.

Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?

by Zacks Equity Research

HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.

Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?

by Zacks Equity Research

Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.

Why Cencora (COR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Cencora (COR) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Cencora (COR) Stock Nosedives: Here's What Caused the Decline

by Zacks Equity Research

Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.